It's our final show of 2018.
So, of course, Jim Cramer's gotta cover all of his bases before he heads off to vacation.
The Post-Fed Hangover
The markets are feeling the Fed's decision to hike rates Wednesday, Dec. 20.
"So now we have to make the best of it. We have to try to figure out how to make money even though the Fed is going to make it harder -- not by its focus on the dots and the models, but by ignoring critical warning signs that are pretty much everywhere. Of course, in their view they aren't ignoring anything," Cramer wrote in his morning column for Real Money.
Cramer breaks down his thoughts on the Fed, and why he wants to sit down for lunch with Fed Chair Jerome Powell.
Hint: It's not just to criticize the hikes.
Tilray's Deal With Anheuser-Busch
Tilray is Real Money's stock of the day.
The research partnership will explore non-alcoholic beverages that contain THC and CBD, both key chemicals found in marijuana but with very different effects. THC is the psychoactive chemical in marijuana the produces the high, while CBD is non-psychoactive and blocks the high.
As part of the deal, each company will pitch in $50 million, with Tilray taking part through its subsidiary, High Park Co., which develops, distributes and sells cannabis products in Canada.
"We are delighted to be joining forces with a world-leading beverage company, AB InBev, to research how to create enjoyable cannabis beverage products," said Brendan Kennedy, CEO of Tilray, in a press release.
Altria's Deal With Juul
TheStreet's Joseph Woelfel reported on the new deal.
Altria's investment represents a 35% stake in JUUL.
The deal values Juul at more than double the roughly $16 billion valuation it received in July in a private funding round, according to Reuters.